| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17673432 | IVR | 2 mg/kg | - | No significant effects observed | - |
| IVR | 100 mg/kg | 100 mg/kg | Erectile dysfunction | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Erectile dysfunction | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:20732377 | IVTH | 0.00000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 - 0.00001 M | 0.0000001 - 0.00001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:28396216 | IVTH | 0.00000000001 - 0.00001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:29338944 | IVR | 30 mg/kg | 30 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations |
| IVR | 30 mg/kg | 30 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 30 mg/kg | 30 mg/kg | Decreased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations | |
| PMID:31371049 | IVTH | 0.0001 M | 0.0001 M | Affects endometrial development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 M | - | No significant effects observed | - | |
| IVTH | 0.00005 M | 0.00005 M | Affects endometrial development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:31533020 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased weights of vagina | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| PMID:35932513 | IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increase in the number of abnormal sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Reduced sperm quality | Reproductive endocrine-mediated perturbations | |
| PMID:36843954 | IVTH | 0.000058 M | 0.000058 M | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000058 M | 0.000058 M | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| PMID:37819454 | IVTH | 0.0001 M | 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.